Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02304419 · ClinicalTrials.gov registry record · Phase 1
A Study of Galunisertib on the Immune System in Participants With Cancer
A Phase 1 study of Neoplasm, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02304419 is a Phase 1 study of Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02304419, a Phase 1 study of Neoplasm, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
Conditions Studied
Interventions
- DRUG Galunisertib
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02304419
The ClinicalTrials.gov registry entry for NCT02304419 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Galunisertib is the first listed.
NCT02304419 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02304419 about?
NCT02304419 is a clinical study titled "A Study of Galunisertib on the Immune System in Participants With Cancer". The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
What is the current status of trial NCT02304419?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-05. Estimated completion is 2016-08.
What conditions does trial NCT02304419 study?
This clinical trial studies the following conditions: Neoplasm.
What interventions are being tested in trial NCT02304419?
The interventions under investigation include: Galunisertib (DRUG).
Who is sponsoring clinical trial NCT02304419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02304419 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
-
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
COMPLETED · Phase 1
-
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
COMPLETED · Phase 1
-
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.